Over the past year, numerous studies in the peer reviewed and preprint literature have
reported on the virological, epidemiological and clinical characteristics of the coronavirus …

Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …

Liver metastasis, the leading cause of colorectal cancer mortality, exhibits a highly
heterogeneous and suppressive immune microenvironment. Here, we sequenced 97 …

Understanding adaptive immunity to SARS-CoV-2 is important for vaccine development,
interpreting coronavirus disease 2019 (COVID-19) pathogenesis, and calibration of …

Effective countermeasures against the recent emergence and rapid expansion of the 2019
novel coronavirus (SARS-CoV-2) require the development of data and tools to understand …

INTRODUCTION Immunotherapy targeting the programmed cell death protein–1 (PD-1) axis
elicits durable antitumor responses in multiple cancer types. However, clinical responses …

Background Patients with lung cancers may have disproportionately severe coronavirus
disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific …

CD8+ T cell–dependent killing of cancer cells requires efficient presentation of tumor
antigens by human leukocyte antigen class I (HLA-I) molecules. However, the extent to …

An important challenge in the real-world management of patients with advanced clear-cell
renal cell carcinoma (aRCC) is determining who might benefit from immune checkpoint …

Despite impressive durable responses, immune checkpoint inhibitors do not provide a long-
term benefit to the majority of patients with cancer. Understanding genomic correlates of …